Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Greenville, North Carolina Clinical Trials

A listing of Greenville, North Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (132) clinical trials

Hemodynamic-GUIDEd Management of Heart Failure

The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS HF System in an expanded patient population including HF patients outside of the present indication, but at risk for future HF events or mortality. The trial includes patients with New York Heart Association (NYHA) Class II, ...

Phase N/A

2.29 miles

Learn More »

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Phase

2.51 miles

Learn More »

Alvocidib Biomarker-driven Phase 2 AML Study

In Stage 1 of the study, all eligible AML patients with demonstrated MCL-1 dependence of 40% by mitochondrial profiling in bone marrow will receive treatment with ACM. In Stage 2, all eligible AML patients with demonstrated MCL-1 dependence of 40% by mitochondrial profiling in bone marrow will be randomized 1:1 ...

Phase

2.51 miles

Learn More »

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

The objective is to demonstrate the non-inferiority of edoxaban to standard of care (SOC; including low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors) in the treatment and secondary prevention of VTE in pediatric subjects with regard to the composite efficacy endpoint (ie, symptomatic ...

Phase

2.51 miles

Learn More »

Study of Kidney Tumors in Younger Patients

PRIMARY OBJECTIVES: I. Classify patients with renal tumors by histological categorization, surgico-pathological stage, presence of metastases, age at diagnosis, tumor weight, and loss of heterozygosity for chromosomes 1p and 16q, to define eligibility for a series of therapeutic studies. (Loss of heterozygosity [LOH] testing discontinued as of April 2014) II. ...

Phase N/A

2.51 miles

Learn More »

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

PRIMARY OBJECTIVES: I. To prospectively analyze the factors that are currently used for risk-group assignment (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog [MYCN] copy number by fluorescent in situ hybridization [FISH], deoxyribonucleic acid [DNA] content by flow cytometry, and tumor histology using the International Neuroblastoma Pathologic Classification System) in ...

Phase N/A

2.51 miles

Learn More »

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

The purpose of this study is to test how different doses of a statin, Lipitor, affect muscle health and function, and cardiovascular fitness.

Phase

2.51 miles

Learn More »

Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

This is a Phase 3, multi-center, randomized, double-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium in 25% ethanol solution. Mino-Lok Therapy is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated ...

Phase

2.51 miles

Learn More »

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa.

Phase

2.51 miles

Learn More »

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

PRIMARY OBJECTIVES: I. To assess the efficacy as measured by the confirmed overall hematologic response rate (partial response or better) of isatuximab in relapsed/refractory systemic light chain (AL) amyloidosis. SECONDARY OBJECTIVES: I. To evaluate toxicities in the treatment of relapsed/refractory AL amyloidosis with isatuximab. II. To evaluate time to hematologic ...

Phase

2.51 miles

Learn More »